Skip to main content
Fachgebiete
Automobil + Motoren Bauwesen + Immobilien Business IT + Informatik Elektrotechnik + Elektronik Energie + Nachhaltigkeit Finance + Banking Management + Führung Marketing + Vertrieb Maschinenbau + Werkstoffe Versicherung + Risiko
DE
EN
Bücher
Zeitschriften
Themenseiten
Organisationspsychologie Projektmanagement Marketing Smart Manufacturing
Weitere Formate
Podcasts Webinare Technik Webinare Wirtschaft Kongresse Veranstaltungskalender Awards
Jetzt Einzelzugang starten
Zugang für Unternehmen
Referenzkunden
SLX-Digitalkonferenz: Zukunftswerkstatt 2024

Mehr Umsatz mit Top-Kontakten

Am 7. Mai erfahren Sie, wie Vertriebsteams Leadgenerierung, Leadnurturing und Leadstrategien effizient steuern können.
Erweiterte Suche
Anmelden
nach oben
Erschienen in:
Nonautonomous Dynamical Systems in the Life Sciences Kapitel lesen Erstes Kapitel lesen

2013 | OriginalPaper | Buchkapitel

7. Mathematical Concepts in Pharmacokinetics and Pharmacodynamics with Application to Tumor Growth

verfasst von : Gilbert Koch, Johannes Schropp

Erschienen in: Nonautonomous Dynamical Systems in the Life Sciences

Verlag: Springer International Publishing

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config
loading …

Abstract

Mathematical modeling plays an important and increasing role in drug development. The objective of this chapter is to present the concept of pharmacokinetic (PK) and pharmacodynamic (PD) modeling applied in the pharmaceutical industry. We will introduce typically PK and PD models and present the underlying pharmacological and biological interpretation. It turns out that any PKPD model is a nonautonomous dynamical system driven by the drug concentration. We state a theoretical result describing the general relationship between two widely used models, namely, transit compartments and lifespan models. Further, we develop a PKPD model for tumor growth and anticancer effects based on the present model figures and apply the model to measured data.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 340 Zeitschriften

aus folgenden Fachgebieten:

  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Versicherung + Risiko




Jetzt Wissensvorsprung sichern!

Jetzt informieren
Vorheriges Kapitel Multisite Mechanisms for Ultrasensitivity in Signal Transduction
Nächstes Kapitel Viral Kinetic Modeling of Chronic Hepatitis C and B Infection
Literatur
1.
J.S. Barrett, O. Della Casa Alberighi, S. Läer, B. Meibohm, Physiologically based pharmacokinetic (PBPK) modeling in children. Clin. Pharmacol. Ther. 92, 40–49 (2012)
2.
P.L. Bonate, Pharmacokinetic-Pharmacodynamic Modeling and Simulation (Springer, London, 2006)
3.
P.L. Bonate, D.R. Howard, Pharmacokinetics in Drug Development: Advances and Applications, vol. 3 (Springer, Berlin, 2011)CrossRef
4.
M.E. Burton, L.M. Shaw, J.J. Schentag, W.E. Evans, Applied Pharmacokinetics & Pharmacodynamics: Principles of Therapeutic Drug Monitoring (Lippincott Williams & Wilkins, Philadelphia, 2006)
5.
E.A. Coddington, N. Levinson, Theory of Ordinary Differential Equations (McGraw-Hill, New York, 1955)MATH
6.
M. Danhof, J. de Jongh, E.C.M. De Lange, O. Della Pasqua, B.A. Ploeger, R.A. Voskuyl, Mechanism-based pharmacokinetic-pharmacodynamic modeling: Biophase distribution, receptor theory, and dynamical systems analysis. Annu. Rev. Pharmacol. Toxicol. 47, 357–400 (2007)CrossRef
7.
M. Danhof, E.C.M. de Lange, O.E. Della Pasqua, B.A. Ploeger, R.A. Voskuyl, Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. Trends Pharmacol. Sci. 29, 186–191 (2008)CrossRef
8.
N.L. Dayneka, V. Garg, W.J. Jusko, Comparison of four basic models of indirect pharmacodynamic responses. J. Pharmacokinet. Biopharm. 21, 457–478 (1993)CrossRef
9.
J.A. DiMasi, R.W. Hansen, H.G. Grabowski, The price of innovation: New estimates of drug development costs. J. Health Econ. 22, 151–185 (2003)CrossRef
10.
F.H. Dost, Der Blutspiegel: Kinetik der Konzentrationsabläufe in der Kreislaufflüssigkeit (Georg Thieme, Leipzig, 1953)
11.
F.H. Dost, Grundlagen der Pharmakokinetik (Georg Thieme, Stuttgart, 1968)
12.
J.C. Earp, D.C. DuBois, D.S. Molano, N.A. Pyszczynski, C.E. Keller, R.R. Almon, W.J. Jusko, Modeling corticosteroid effects in a rat model of rheumatoid arthritis I: Mechanistic disease progression model for the time course of collagen-induced arthritis in Lewis rats. J. Pharmacol. Exp. Ther. 326, 532–545 (2008)CrossRef
13.
N. Frances, L. Claret, R. Bruno, A. Iliadis, Tumor growth modeling from clinical trials reveals synergistic anticancer effect of the capecitabine and docetaxel combination in metastatic breast cancer. Cancer Chemother. Pharmacol. 68, 1413–1419 (2011)CrossRef
14.
J. Gabrielsson, D. Weiner, Pharmacokinetic and pharmacodynamic data analysis: Concepts and applications (Swedish Pharmaceutical Press, Stockholm, 2006)
15.
M. Gibaldi, D. Perrier, Pharmacokinetics Second Edition Revised and Expanded (Marcel Dekker, New York, 1982)CrossRef
16.
J.V.S. Gobburu, P.J. Marroum, Utilisation of pharmacokinetic-pharmacodynamic modelling and simulation in regulatory decision-making. Clin. Pharmacokinet. 40, 883–892 (2001)CrossRef
17.
K. Goteti, C.E. Garner, L. Utley, J. Dai, S. Ashwell, D.T. Moustakas, M. Gönen, G. Schwartz, S.E. Kern, S. Zabludoff, P.J. Brassil, Preclinical pharmacokinetic/pharmacodynamic models to predict synergistic effects of co-administered anti-cancer agents. Cancer Chemother. Pharmacol. 66, 245–254 (2010)CrossRef
18.
S.A. Hill, Pharmacokinetics of drug infusions. Continuing Educ. Anaesth. Crit. Care Pain 4, 76–80 (2004)CrossRef
19.
H.M. Jones, I.B. Gardner, K.J. Watson, Modelling and PBPK simulation in drug discovery. Astron. Astrophys. Suppl. 11, 155–166 (2009)
20.
21.
G. Koch, J. Schropp, General relationship between transit compartments and lifespan models. J. Pharmacokinet. Pharmacodyn. 39, 343–355 (2012)CrossRef
22.
G. Koch, A. Walz, G. Lahu, J. Schropp, Modeling of tumor growth and anticancer effects of combination therapy. J. Pharmacokinet. Pharmacodyn. 36, 179–197 (2009)CrossRef
23.
I. Kola, J. Landis, Can the pharmaceutical industry reduce the attrition rates? Nat. Rev. Drug Discov. 3, 711–715 (2004)CrossRef
24.
W. Krzyzanski, Interpretation of transit compartments pharmacodynamic models as lifespan based indirect response models. J. Pharmacokinet. Pharmacodyn. 38, 179–204 (2011)CrossRef
25.
W. Krzyzanski, J.J. Perez Ruixo, Lifespan based indirect response models. J. Pharmacokinet. Pharmacodyn. 39, 109–123 (2012)CrossRef
26.
W. Krzyzanski, R. Ramakrishnan, W.J. Jusko, Basic pharmacodynamic models for agents that alter production of natural cells. J. Pharmacokinet. Biopharm. 27, 467–489 (1999)CrossRef
27.
W. Krzyzanski, S. Woo, W.J. Jusko, Pharmacodynamic models for agents that alter production of natural cells with various distributions of lifespans. J. Pharmacokinet. Pharmacodyn. 33, 125–166 (2006)CrossRef
28.
Y. Kwon, Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists (Springer, New York, 2001)
29.
A.K. Laird, Dynamics of tumor growth. Br. J. Cancer 18, 490–502 (1964)CrossRef
30.
E.D. Lobo, J.P. Balthasar, Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro. AAPS PharmSci. 4, 212–222 (2002)CrossRef
31.
P. Macheras, A. Iliadis, in Modeling in Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics. Interdisciplinary Applied Mathematics, vol. 30 (Springer, Berlin, 2006)
32.
D.E. Mager, E. Wyska, W.J. Jusko, Diversity of mechanism-based pharmacodynamic models. Drug Metab. Dispos. 31, 510–519 (2003)CrossRef
33.
J. Mordenti, S.A. Chen, J.A. Moore, B.L. Ferraiolo, J.D. Green, Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm. Res. 8, 1351–1359 (1991)CrossRef
34.
B.A. Ploeger, P.H. van der Graaf, M. Danhof, Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling. Drug Metab. Pharmacokinet. 24, 3–15 (2009)CrossRef
35.
R.M. Savic, D.M. Jonker, T. Kerbusch, M.O. Karlsson, Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34, 711–726 (2007)CrossRef
36.
L.B. Sheiner, D.R. Stanski, S. Vozeh, R.D. Miller, J. Ham, Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin. Pharmacol. Ther. 25, 358–371 (1979)
37.
M. Simeoni, P. Magni, C. Cammia, G. De Nicolao, V. Croci, E. Pesenti, M. Germani, I. Poggesi, M. Rocchetti, Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res. 64, 1094–1101 (2004)CrossRef
38.
Y. Sun, W.J. Jusko, Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J. Pharm. Sci. 87, 732–737 (1998)CrossRef
39.
T. Teorell, Kinetics of distribution of substances administered to the body I. The extravascular modes of administration. Archs. Int. Pharmacodyn. Ther. 57, 205–225 (1937)
40.
P.H. van der Graaf, J. Gabrielsson, Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development. Future Med. Chem. 1, 1371–1374 (2009)CrossRef
41.
J.G. Wagner, History of pharmacokinetics. Pharmacol. Ther. 12, 537–562 (1981)
42.
G.B. West, J.H. Brown, The origin of allometric scaling laws in biology from genomes to ecosystems: Towards a quantitative unifying theory of biological structure and organization. J. Exp. Biol. 208, 1575–1592 (2005)CrossRef
43.
T.E. Wheldon, Mathematical Models in Cancer Research (Adam Hilger, Bristol/Philadelphia, 1988)MATH
Metadaten
Titel
Mathematical Concepts in Pharmacokinetics and Pharmacodynamics with Application to Tumor Growth
verfasst von
Gilbert Koch
Johannes Schropp
Copyright-Jahr
2013
Buch
Nonautonomous Dynamical Systems in the Life Sciences

Print ISBN: 978-3-319-03079-1

Electronic ISBN: 978-3-319-03080-7

Copyright-Jahr: 2013

DOI
https://doi.org/10.1007/978-3-319-03080-7_7